{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:09:51Z","timestamp":1787026191808,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated respiratory allergy, but real-world use is limited by access and adherence. Telemedicine-enabled sublingual immunotherapy (SLIT) may address these barriers; long-term outcomes remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective longitudinal cohort study of adults receiving personalized SLIT via a telemedicine platform (2020\u20132025). Participants with \u22651 baseline and \u22651 follow-up after \u226512 months of treatment were included (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092,897). Outcomes included symptom severity, medication use, quality of life (QoL), adherence, and adverse events. Longitudinal changes were analyzed using mixed-effects models; asthma subgroup analyses were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age was 39.0 years, 52.7% were female, and 25.3% had asthma. Median follow-up was 20 months. Symptom severity decreased, with a 10.1-point reduction at 6 months and smaller subsequent declines. Clinically meaningful improvement (\u226530-point reduction) increased from 28% at 12 months to 45% at 24 months; higher baseline severity predicted earlier response (HR 2.95). Medication use declined over time (OR 2.31 per 12 months), with fewer medication categories used. QoL improvement increased from 81.4% at 12\u201318 months to 90.7% at 30\u201336 months (OR 4.68 per 12 months). Self-reported adherence was high (&amp;gt;90% for \u226520 days\/month), and discontinuation was uncommon. Adverse events were infrequent and predominantly mild (Grade I: 11.7%); no anaphylaxis or eosinophilic esophagitis was reported. Among patients with asthma, longer treatment duration was associated with improved control, reduced inhaler use, and improved QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Personalized SLIT delivered via telemedicine was associated with sustained symptom improvement, reduced medication use, high adherence, and a favorable safety profile, supporting the feasibility and scalability of this care model in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1865860","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:37:54Z","timestamp":1781069874000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform: a retrospective longitudinal cohort study"],"prefix":"10.3389","volume":"7","author":[{"given":"Chet","family":"Tharpe","sequence":"first","affiliation":[{"name":"Curex Inc","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Davidson","sequence":"additional","affiliation":[{"name":"Curex Inc","place":["New York, NY, United States"]},{"name":"Pulmonary & Critical Care, BronxCare Health System","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Mardaga","sequence":"additional","affiliation":[{"name":"Curex Inc","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Solow","sequence":"additional","affiliation":[{"name":"Curex Inc","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Kakaulin","sequence":"additional","affiliation":[{"name":"Curex Inc","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Kruzick","sequence":"additional","affiliation":[{"name":"Curex Inc","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Herold","sequence":"additional","affiliation":[{"name":"Curex Inc","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Snyder","sequence":"additional","affiliation":[{"name":"Curex Inc","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagrat","family":"Hakobyan","sequence":"additional","affiliation":[{"name":"Medical Research & Biostatistics, Arx Sciartis LLC","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.iac.2015.12.002","article-title":"Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunology and allergy clinics of North America","volume":"36","author":"Meltzer","year":"2016","journal-title":"Rhinitis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJM199908123410702","article-title":"Long-Term clinical efficacy of grass-pollen immunotherapy","volume":"341","author":"Durham","year":"1999","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1398-9995.2007.01451.x","article-title":"Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study","volume":"62","author":"Jacobsen","year":"2007","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD001936","DOI":"10.1002\/14651858.CD001936.pub2","article-title":"Allergen injection immunotherapy for seasonal allergic rhinitis","volume":"2007","author":"Calderon","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002893.pub2","article-title":"Sublingual immunotherapy for allergic rhinitis","author":"Radulovic","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1517\/14740338.2015.1017468","article-title":"Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review","volume":"14","author":"Didier","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","article-title":"Allergen immunotherapy: a practice parameter third update","volume":"127","author":"Cox","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jaci.2008.12.013","article-title":"Multiallergen immunotherapy for allergic rhinitis and asthma","volume":"123","author":"Nelson","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/ACI.0b013e328332b8df","article-title":"Evidence of adherence to allergen-specific immunotherapy","volume":"9","author":"Senna","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaci.2013.03.013","article-title":"Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy","volume":"132","author":"Kiel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-World evidence \u2014 what is it and what can it tell US?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1586\/1744666X.2014.982536","article-title":"Sublingual allergen immunotherapy for respiratory allergies: what is new?","volume":"10","author":"Makatsori","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B15","author":"Glacy","year":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite\u2013induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/jama.2016.21040","article-title":"Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial","volume":"317","author":"Scadding","year":"2017","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1378\/chest.06-1425","article-title":"Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age","volume":"133","author":"Penagos","year":"2008","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001186.pub2","article-title":"Injection allergen immunotherapy for asthma","author":"Abramson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101334","DOI":"10.1016\/j.smim.2019.101334","article-title":"Allergen immunotherapy (AIT) in asthma","volume":"46","author":"Virchow","year":"2019","journal-title":"Semin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaci.2015.04.047","article-title":"International consensus on allergy immunotherapy","volume":"136","author":"Jutel","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11596-017-1748-2","article-title":"Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis","volume":"37","author":"Wang","year":"2017","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jaci.2009.04.037","article-title":"Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract","volume":"124","author":"Amar","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/ACI.0000000000000018","article-title":"The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis: review of the evidence","volume":"14","author":"Passalacqua","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100766","DOI":"10.1016\/j.waojou.2023.100766","article-title":"Comparison of allergen immunotherapy practice patterns in inhalant allergies in the United States of America and Europe: similarities and differences 2023","volume":"16","author":"Pfaar","year":"2023","journal-title":"World Allergy Organization Journal"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/ohn.648","article-title":"Clinical practice guideline: immunotherapy for inhalant allergy","volume":"170","author":"Gurgel","year":"2024","journal-title":"Otolaryngol.\u2013Head Neck Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.3390\/jcm13237268","article-title":"A modern approach to clinical outcome assessment in allergy management: advantages of allergen exposure chambers","volume":"13","author":"Zemelka-Wiacek","year":"2024","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/all.12373","article-title":"Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure","volume":"69","author":"Durham","year":"2014","journal-title":"Allergy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100275","DOI":"10.1016\/j.lanepe.2021.100275","article-title":"Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study","volume":"13","author":"Fritzsching","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11882-015-0586-1","article-title":"Adherence to sublingual immunotherapy","volume":"16","author":"Incorvaia","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1081-1206(10)61440-8","article-title":"Efficacy and safety of sublingual immunotherapy","volume":"93","author":"Passalacqua","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1398-9995.2003.00420.x","article-title":"Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects","volume":"59","author":"Downie","year":"2004","journal-title":"Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/JMDH.S104807","article-title":"Information bias in health research: definition, pitfalls, and adjustment methods","volume":"9","author":"Althubaiti","year":"2016","journal-title":"J Multidiscip Healthc"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1865860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:37:56Z","timestamp":1781069876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1865860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":33,"alternative-id":["10.3389\/falgy.2026.1865860"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1865860","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1865860"}}